Taysha Gene Therapies

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Taysha Gene Therapies advances TSHA-102 trials, secures financial stability

Taysha Gene Therapies showcased positive TSHA-102 trial results, faced financial challenges with increased expenses, and highlighted the potential of gene therapy in treating Rett syndrome. The company's focus on safety, sustained improvements, and regulatory advancements positions it for future success.

Taysha Gene Therapies reports positive TSHA-102 data and financial growth

Taysha Gene Therapies showcased promising advancements in the TSHA-102 program for Rett syndrome, supported by positive clinical data and a strengthened financial position.
While challenges exist in regulatory clarity and cost management, the company's strategic focus on data integrity and patient safety bodes well for future growth.
Opportunities for expansion, regulatory milestones, and market positioning through effective resource allocation and research advancements position Taysha for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why

Taysha Gene Therapies' TSHA-102 shows promising results for Rett syndrome, leveraging miRARE technology to modulate MECP2 expression, improving patients' quality of life in Phase 1/2 trials. TSHA-102's unique miRNA-responsive auto-regulatory feature ensures safe MECP2 levels, with intrathecal administration targeting CNS cells, minimizing systemic adverse effects. Despite recent stock price decline, TSHA has a solid cash runway and potential market, with key catalysts expected by late 2024 and 1H2025.

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Pacific Biosciences of California

Yalla Group

Have you thought about adding penny stocks to your portfolio? You may be onto something. That is, as long as you choose the right stock picks. But there are risks to consider too.

3 Penny Stocks to Buy With $100

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.38 per share a year ago.

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates

Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering at the public offering price, less the underwriting discount. The gross proceeds from the offering to Taysha are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter's option to purchase additional shares. The offering is expected to close on or about June 27, 2024, subject to customary closing conditions.

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies (NASDAQ: TSHA ) stock is taking a beating on Wednesday after the gene therapy company announced a proposed public offering for its shares. Taysha Gene Therapies says that it intends to offer up to $75 million worth of TSHA stock in this offering.

Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?

General Mills

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday.

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Tuesday, Taysha Gene Therapies Inc TSHA released longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome.

What's Going On With Taysha Gene Therapies Stock Tuesday?

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Geron

Nerdy

Many investors can't figure out how to invest in penny stocks because they don't know what to look for. Some penny stocks are companies in beginning phases that have yet to scale up operations.

How to Invest in Penny Stocks in 2024: 3 Best Picks

Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D.

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer and Chairman Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Salveen Richter - Goldman Sachs Whitney Ijem - Canaccord Genuity Joon Lee - Truist Securities Maury Raycroft - Jefferies Christopher Raymond - Piper Sandler Gil Blum - Needham and Company Yanan Zhu - Wells Fargo Jack Allen - Baird Silvan Tuerkcan - JMP Securities Operator Greetings and welcome to the Taysha Gene Therapies First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.28 per share a year ago.

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10 15 total vg) with dosing scheduled for Q2 2024

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern Time.

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric)

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of TSHA-102 treating pediatric patients with Rett Syndrome in phase 1/2 REVEAL study expected mid-2024; Cohort 2 higher dose data 2nd half of 2024. The global Rett Syndrome market is expected to reach $515.06 million by 2029.

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six

News for Taysha Gene Therapies Stock (TSHA)